[Announcement+] IntronBio's Cumulative Q3 Sales Reach 33.6 Billion KRW... 447% Increase YoY

Growth in Key Cash Cow Performance Including Diagnostic Products and Alternatives to Veterinary Antibiotics

[Asia Economy Reporter Eunmo Koo] Intronbio announced on the 27th through a public disclosure that its cumulative sales for the third quarter of this year were tentatively estimated at 33.629 billion KRW, a 447% increase compared to the same period last year. Operating profit for the same period turned positive at 11.722 billion KRW.

An Intronbio official stated, “This year, the performance of major cash cow businesses such as molecular diagnostic products, molecular diagnostic kits, and animal antibiotic alternatives increased, resulting in significant growth compared to the same period last year,” adding, “The growth in the company’s major cash cow business performance drove this earnings growth.”

In particular, sales of molecular diagnostic products in the third quarter increased by 843% to 19.159 billion KRW, sales of molecular diagnostic kits increased by 497% to 6.337 billion KRW, and sales of the animal antibiotic alternative ‘PML100’ also rose by 816% to 1.47 billion KRW.

Meanwhile, third-quarter sales amounted to 7.07 billion KRW, and operating profit was 891 million KRW. Compared to the same period last year, sales grew by 276%, and operating profit turned positive.

This content was produced with the assistance of AI translation services.